DAILY VOLUME INDEX
Trading: SELL @ $19.26
Signal Strength: STRONG
Grifols (NASDAQ:GRFS) current price has highlighted the commencement of distribution and the start of bearish trading conditions. Currently, the DVI is -1324.
A bearish crossover has been confirmed due the last trading session with is a strong indication of a diretional change. This indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
The daily volume index (DVI) is the amount of individual securities traded in a day on average over a specified period of time. Trading activity relates to the liquidity of a security. When average daily trading volume is high the stock can be easily traded and has high liquidity if trading volume is not very high and the security will tend to be less expensive because people are not as willing to buy it. As a result average daily trading volume can have an effect on the price of the security.
Calculation: Daily Volume Index (DVI):
1) [Close]-[Average price] / [Average price] x [Volume];
PROFILE: Grifols (GRFS)
Stock Exchange: NASDAQ
Ticker Codes: | GRFS | NASDAQ:GRFS |
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Daily Volume IndexDownload
|NVAX Novavax Inc||0.64||16.4||56,273,525||-71,614||BEARISH|
|BLCM Bellicum Pharma||4.09||13||905,767||-22||BEARISH|
|GOGL Golden Ocean||5.32||6||409,841||-244||BEARISH|
|ERI Eldorado Resorts||48.19||4.4||1,363,345||-4,307||BEARISH|
|NNBR Nn Inc||7.82||4.1||504,819||-11,741||BEARISH|
|SND Smart Sand Inc||4.42||3.8||544,630||-1,045||BEARISH|
|MGPI Mgp Ingredients Inc||77.01||3.3||276,463||-745||BEARISH|
|MELI Mercadolibre Inc||497.95||3.2||758,358||-5,769||BEARISH|